



Evrysdi in Saudi Arabia

The SFDA named-patient coordination pathway — indicative 2026

RARE DISEASE · ORAL SMN2 SPLICING MODIFIER FOR SMA

The clinical situation

Evrysdi (risdiplam) is an oral SMN2 pre-mRNA splicing modifier for spinal muscular atrophy across all ages, including infants from birth. Manufactured by Roche/Genentech. Supplied as an oral solution reconstituted by pharmacy; dose is weight- and age-titrated, taken once daily after a meal. Embryo-fetal toxicity requires contraception counselling. Lifelong therapy; gaps in supply reduce motor and respiratory benefit.

The pathway, 5 steps

- 1 Consultation & SMN1 genotyping.** Your neurology team confirms biallelic SMN1 mutation, SMN2 copy number, age, and weight for dose calculation.
- 2 Baseline assessment.** Motor milestone scoring (CHOP-INTEND/HFMSE/RULM), respiratory baseline, and contraception counselling where applicable.
- 3 SFDA named-patient application.** Clinical rationale, genotype report, and dosing plan filed under personal-use import.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates refills through our US-licensed DSCSA-compliant specialty wholesale partner; refrigerated cold-chain of reconstituted product.
- 5 Initiation & continuity.** Neurology team initiates and trains the family on reconstitution and dosing; continuity planning for lifelong supply.

Indicative economics

Reference US cash-pay range: USD 340,000–360,000 per year at average adult weight-dosing (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete SFDA application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your neurology team and SFDA review, keyed to SMN1 genotype, SMN2 copy number, and weight. **Logistics.** Refrigerated cold-chain shipment with importer-of-record handling and continuity planning. **Concierge case lead.** Named point of contact for the family and care team. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Evrysdi × Saudi Arabia first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/evrysdi-saudi-arabia.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team